Intermittent dosing of glucocorticoid receptor modulators for the treatment of ovarian and other cancers
Номер патента: EP4401734A1
Опубликовано: 24-07-2024
Автор(ы): Joseph K. Belanoff, Stacie SHEPHERD
Принадлежит: Corcept Therapeutics Inc
Опубликовано: 24-07-2024
Автор(ы): Joseph K. Belanoff, Stacie SHEPHERD
Принадлежит: Corcept Therapeutics Inc
Реферат: Methods and compositions for treating cancer (e.g., ovarian, fallopian tube, uterine, cervical, vaginal, vulvar, or peritoneal cancer) are disclosed. The methods include intermittent administration of a glucocorticoid receptor modulator (GRM), such as a non-steroidal GRM (e.g., relacorilant), which may be orally administered, along with a cancer chemotherapy agent to the patient. The patient may have received bevacizumab prior to receiving such intermittent GRM plus chemotherapy treatment. The GRM may be administered: at intervals separated by at least one day without GRM administration; by a schedule linked to the cancer chemotherapy schedule (e.g., a weekly chemotherapy regimen); the day of, or the day before, or the day after, chemotherapy administration; by combinations thereof; and/or on other days. Ovarian cancer patients receiving intermittent relacorilant administration along with nab-paclitaxel administration had improved overall survival, progression free survival, duration of response, and other benefits as compared to patients not receiving relacorilant while receiving nab-paclitaxel.
Medicaments for the prevention or treatment of heart failure comprising administration of an anticholinergic
Номер патента: CA2594693A1. Автор: Steven Kesten,Klaus Viel. Владелец: Individual. Дата публикации: 2006-08-03.